Dengue Viral Infection and Necessity for Screening Patients Having Pyrexia of Unknown Origin

Humaira ZAFAR; Kiran Tauseef BUKHARİ; Sadaf HUMAYOUN; Nouman NOOR; Noor Khan LAKHNANA

doi:https://doi.org/10.5455/umj.20170608022332

Makale detayları

Dengue Viral Infection and Necessity for Screening Patients Having Pyrexia of Unknown Origin

Yazarlar:

Humaira ZAFAR | Kiran Tauseef BUKHARİ | Sadaf HUMAYOUN | Nouman NOOR | Noor Khan LAKHNANA

Yayıncı:

Kemal Türker ULUTAŞ

Dergi:

The Ulutas Medical Journal 2017 Vol.3 Issue 3, pp.49-53

Belge Tipi:

Makale

Yayın Tarihi:

6/2017

Belge Dili:

İngilizce

Document ID (Org No.):

2000802842

Sıklık:

Üç Aylık

eISSN:

2149-388X

pISSN:

2149-0430

DOI:

https://doi.org/10.5455/umj.20170608022332

Özet:

 

Dengue Viral Infection  DVI  is an emerging global health problem infecting about 50-100 million people annually worldwide. More than 2.5 million people have dengue hemorrhagic fever  DHF  and dengue shock syndrome  DSS . Aedesaegypti is the principal vector for disease transmission while humans are the main reservoir. The clinical manifestations range from self-limited Dengue fever  DF  to complicated and fatal outcomes, DHF and DSS. DF is prevalent in more than 100 countries of the world. More than 2.5 billion people of the Worlds population are residents of Dengue endemic area. According to one reported study, the prevalence of DF in Pakistan is 29%. Similarly, one study result carried out in India has shown 78% prevalence of DF. In Mexico, the one published seroprevalence study showed 79.6% prevalence of DF. A review/analysis report of the Gynecological and Obstetrical survey from 30 published studies has shown 64% transmission rate of DF from a mother to a child. The study results carried out in Jamaica has shown an increase in the prevalence of DF in seen in less than 1year and more than 60 years. The mortality rate with DHF is 33%. While in less than 15 years of it is 5%. This can be only reduced with early/accurate diagnosis and the prompt management of the condition. The absence of specific vaccine and antiviral is responsible for making this infection as a global health problem. The US government has spent 15 million US dollars for the establishment and discovery of specific DF treatment. The study carried out in India has shown the median cost for treatment per patient about 432.2 US dollars. It is 4 times in case of private health sectors. The proposed review article will highlight the incidence of dengue infection in patients having PUO  pyrexia of unknown origin . It will be a guide for the clinicians to consider DVI in their list of differential diagnosis of PUO. Moreover, it will be helpful in establishing the screening policies for DVI in PUO. The resultant of all of this will improve the life quality of PUO sufferers. It will be useful to reduce the increased financial burden due to PUO missed diagnosis and management in underdeveloped countries like one of ours.

Makale detayları

Dengue Viral Infection and Necessity for Screening Patients Having Pyrexia of Unknown Origin

Yazarlar: Humaira ZAFAR | Kiran Tauseef BUKHARİ | Sadaf HUMAYOUN | Nouman NOOR | Noor Khan LAKHNANA

Yayıncı: Kemal Türker ULUTAŞ

Dergi: The Ulutas Medical Journal 2017 Vol.3 Issue 3, pp.49-53

Belge Tipi: Makale

Yayın Tarihi: 6/2017

Belge Dili: İngilizce

Document ID (Org No.): 2000802842

Sıklık: Üç Aylık

eISSN: 2149-388X

pISSN: 2149-0430

DOI: https://doi.org/10.5455/umj.20170608022332

Sayı

Yazarlar:

Humaira ZAFAR | Kiran Tauseef BUKHARİ | Sadaf HUMAYOUN | Nouman NOOR | Noor Khan LAKHNANA

Yayıncı:

Kemal Türker ULUTAŞ

Dergi:

The Ulutas Medical Journal 2017 Vol.3 Issue 3, pp.49-53

Belge Tipi:

Makale

Yayın Tarihi:

6/2017

Belge Dili:

İngilizce

Document ID (Org No.):

2000802842

Sıklık:

Üç Aylık

eISSN:

2149-388X

pISSN:

2149-0430

DOI:

https://doi.org/10.5455/umj.20170608022332